[Hereditary gastrointestinal neoplasias].
Hereditary gastrointestinal tumors account for approximately 5 % of the overall gastrointestinal cancer burden. The identification of underlying gene mutations opened up a new dimension regarding prediction and prevention of these hereditary tumors. In this review the current knowledge of epidemiology, clinical findings, pathology and genetic background, surveillance and treatment options of familial adenomatous polyposis (FAP), hereditary non-polyposis colorectal cancer syndrome (HNPCC), hereditary diffuse gastric cancer (HDGC) and familial pancreatic cancer (FPC) are described and discussed.
Fendrich
V
V
Klinik für Visceral-, Thorax- und Gefässchirurgie der Philipps-Universität Marburg.
Bartsch
D K
DK
D011125:Adenomatous Polyposis Coli / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D003106:Colon / Q000473:pathology; D003110:Colonic Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D003123:Colorectal Neoplasms, Hereditary Nonpolyposis / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D004252:DNA Mutational Analysis; D005753:Gastric Mucosa / Q000473:pathology; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology; D010179:Pancreas / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D010375:Pedigree; D013270:Stomach / Q000473:pathology; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology / Q000628:therapy